Form 8-K - Current report:
SEC Accession No. 0000950170-23-003847
Filing Date
2023-02-23
Accepted
2023-02-22 18:15:46
Documents
15
Period of Report
2023-02-22
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acst-20230222.htm   iXBRL 8-K 60355
2 EX-16.1 acst-ex16_1.htm EX-16 7669
3 GRAPHIC img51618503_0.jpg GRAPHIC 31153
4 GRAPHIC img51618503_1.jpg GRAPHIC 1850
  Complete submission text file 0000950170-23-003847.txt   233039

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acst-20230222_pre.xml EX-101.PRE 9851
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acst-20230222.xsd EX-101.SCH 2481
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acst-20230222_lab.xml EX-101.LAB 13360
9 EXTRACTED XBRL INSTANCE DOCUMENT acst-20230222_htm.xml XML 4711
Mailing Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5
Business Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5 450-686-4555
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

EIN.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 23655086
SIC: 2834 Pharmaceutical Preparations